Persistence of Antibodies and Kinetics of B Cell Response in Healthy Children After Vaccination With MCC Vaccine

Prevention of Meningococcal Infection Clinical Trial

Official title:
A Phase IV, Single Centre, Open-label Study to Investigate the Kinetics of the B Cell Response to the C Saccharide Component of Chiron's Meningococcal C Conjugate Vaccine Administered to Healthy Children at Least 12 Months of Age After Priming With a Commercially Available Men ACWY Conjugate Vaccine at 2, 3 and 4 Months of Age

Status Completed

Clinical Trial Summary

Persistence of antibodies and kinetics of B cell response in healthy children after vaccination with MCC vaccine

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention

Related Conditions & MeSH terms

Meningococcal Infections
Prevention of Meningococcal Infection

Clinical Trial Details

NCT number	NCT00310713
Study type	Interventional
Source	Novartis
Contact
Status	Completed
Phase	Phase 4
Start date	April 2006
Completion date	August 2006

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00310674` - Immunogenicity, Safety and Tolerability, of Chiron Meningococcal C Conjugate Vaccine Administered to Healthy Premature and Non Premature Children of 3 Months of Age	Phase 3
Completed	`NCT00311415` - Immunogenicity, Safety, Tolerability and Ability to Prime for Memory of Meningococcal C Conjugate Vaccine in Healthy Children	Phase 3
Completed	`NCT00310687` - Persistence of Immune Response After Vaccination With MCC	Phase 4
Completed	`NCT00310700` - Kinetics of B Cell Response in Infants Menjugate Vaccination	Phase 4
Completed	`NCT00316654` - Persistence of Antibody Response to N. Meningitidis Group C in Children	Phase 4